Merck & Co links with Hisamitsu for alendronate
This article was originally published in Scrip
Executive Summary
Merck & Co's Japanese subsidiary, Banyu, has signed an agreement with Hisamitsu for the co-promotion of its osteoporosis therapy Fosamac (alendronate).